[go: up one dir, main page]

PL2120999T3 - KOMPOZYCJE FARMACEUTYCZNE ZAWIERAJĄCE ANTAGONISTÓW AKTYWINY-ActRIIA I ICH ZASTOSOWANIE W ZAPOBIEGANIU LUB LECZENIU SZPICZAKA MNOGIEGO - Google Patents

KOMPOZYCJE FARMACEUTYCZNE ZAWIERAJĄCE ANTAGONISTÓW AKTYWINY-ActRIIA I ICH ZASTOSOWANIE W ZAPOBIEGANIU LUB LECZENIU SZPICZAKA MNOGIEGO

Info

Publication number
PL2120999T3
PL2120999T3 PL08725055T PL08725055T PL2120999T3 PL 2120999 T3 PL2120999 T3 PL 2120999T3 PL 08725055 T PL08725055 T PL 08725055T PL 08725055 T PL08725055 T PL 08725055T PL 2120999 T3 PL2120999 T3 PL 2120999T3
Authority
PL
Poland
Prior art keywords
activin
preventing
pharmaceutical compositions
multiple myeloma
treating multiple
Prior art date
Application number
PL08725055T
Other languages
English (en)
Inventor
John Knopf
Jasbir Seehra
Ravindra Kumar
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of PL2120999T3 publication Critical patent/PL2120999T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/02—Processing of mobility data, e.g. registration information at HLR [Home Location Register] or VLR [Visitor Location Register]; Transfer of mobility data, e.g. between HLR, VLR or external networks
    • H04W8/08—Mobility data transfer
    • H04W8/082—Mobility data transfer for traffic bypassing of mobility servers, e.g. location registers, home PLMNs or home agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W40/00—Communication routing or communication path finding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W80/00—Wireless network protocols or protocol adaptations to wireless operation
    • H04W80/04—Network layer protocols, e.g. mobile IP [Internet Protocol]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W84/00—Network topologies
    • H04W84/18—Self-organising networks, e.g. ad-hoc networks or sensor networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L2212/00—Encapsulation of packets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
PL08725055T 2007-02-09 2008-02-01 KOMPOZYCJE FARMACEUTYCZNE ZAWIERAJĄCE ANTAGONISTÓW AKTYWINY-ActRIIA I ICH ZASTOSOWANIE W ZAPOBIEGANIU LUB LECZENIU SZPICZAKA MNOGIEGO PL2120999T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US90058007P 2007-02-09 2007-02-09
US93276207P 2007-05-31 2007-05-31
US93736507P 2007-06-26 2007-06-26
US5280707P 2007-10-25 2007-10-25
US52807P 2007-10-25 2007-10-25
EP08725055A EP2120999B1 (en) 2007-02-09 2008-02-01 Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma
PCT/US2008/001354 WO2008100384A2 (en) 2007-02-09 2008-02-01 Activin-actriia antagonists and uses for promoting bone growth in cancer patients

Publications (1)

Publication Number Publication Date
PL2120999T3 true PL2120999T3 (pl) 2013-01-31

Family

ID=39690668

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08725055T PL2120999T3 (pl) 2007-02-09 2008-02-01 KOMPOZYCJE FARMACEUTYCZNE ZAWIERAJĄCE ANTAGONISTÓW AKTYWINY-ActRIIA I ICH ZASTOSOWANIE W ZAPOBIEGANIU LUB LECZENIU SZPICZAKA MNOGIEGO

Country Status (24)

Country Link
US (4) US8173601B2 (pl)
EP (3) EP2120999B1 (pl)
JP (6) JP5574711B2 (pl)
KR (7) KR20160129095A (pl)
CN (3) CN101687016B (pl)
AR (1) AR065289A1 (pl)
AU (1) AU2008216896B2 (pl)
BR (1) BRPI0807506B1 (pl)
CA (3) CA3039330C (pl)
CY (1) CY1113963T1 (pl)
DK (1) DK2120999T3 (pl)
EA (3) EA018221B1 (pl)
ES (2) ES2394123T3 (pl)
HR (1) HRP20120947T1 (pl)
IL (3) IL200242B (pl)
ME (1) ME02333B (pl)
MX (2) MX2009008510A (pl)
PL (1) PL2120999T3 (pl)
PT (1) PT2120999E (pl)
RS (1) RS52535B (pl)
SI (1) SI2120999T1 (pl)
TR (1) TR200906329T1 (pl)
TW (7) TWI606062B (pl)
WO (1) WO2008100384A2 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551852T3 (es) * 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (ru) * 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
EP2468291B1 (en) * 2006-12-18 2017-11-22 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US20100008918A1 (en) 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
NZ590326A (en) 2008-06-26 2013-05-31 Acceleron Pharma Inc Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
EP2387412A4 (en) * 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
CA2773494A1 (en) * 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
CA2779472C (en) * 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
EP4480582A1 (en) 2013-01-18 2024-12-25 Biomeme, Inc. Analytic device
PL3312195T3 (pl) * 2013-03-20 2020-04-30 Genzyme Corporation Sposoby leczenia wrodzonej łamliwości kości
JP2015159766A (ja) * 2014-02-27 2015-09-07 国立大学法人京都大学 クッシング症候群の検査方法、検査用バイオマーカー及び治療剤
JP6649895B2 (ja) 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SMT202300166T1 (it) 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
CA3005975A1 (en) * 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
KR102457751B1 (ko) * 2016-03-10 2022-10-21 악셀레론 파마 인코포레이티드 액티빈 타입 2 수용체 결합 단백질 및 이의 용도
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EP3538123A4 (en) * 2016-11-10 2020-10-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE
GB201620119D0 (en) 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
AU2018214979A1 (en) * 2017-02-01 2019-08-15 Acceleron Pharma Inc. TGFβ and actrii antagonists for use in increasing immune activity
CA3054837A1 (en) 2017-03-24 2018-09-27 Novartis Ag Methods for preventing and treating heart disease
EP3682024A4 (en) 2017-09-15 2021-05-12 Biomeme, Inc. METHODS AND SYSTEMS FOR AUTOMATIC SAMPLE PROCESSING
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN120399032A (zh) 2018-01-12 2025-08-01 科乐斯疗法公司 激活素受体iib型变体及其使用方法
EP3788065B1 (en) 2018-04-30 2025-08-27 The Children's Hospital Of Philadelphia Improving anemias by combining agents
EP3790572A4 (en) 2018-05-09 2022-03-16 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF
AU2019309472A1 (en) * 2018-07-24 2021-03-18 Good T Cells, Inc. Composition for preventing or treating immune-related diseases
JP7483745B2 (ja) 2019-03-21 2024-05-15 バイオミーム インコーポレイテッド 多機能性分析デバイス
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
AU2021245671A1 (en) * 2020-03-31 2022-10-20 Cell Exosome Therapeutics Inc. Cell preservation method
EP4213989A4 (en) 2020-09-18 2025-01-15 Biomeme, Inc. Portable devices and methods for analyzing samples
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
CA3228901A1 (en) * 2021-09-03 2023-03-09 Chris Xiangyang Lu Anti-acvr2a antibodies and uses thereof

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637520B2 (ja) * 1985-07-03 1994-05-18 味の素株式会社 ポリペプチド
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1992004913A1 (en) 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
WO1992020793A1 (en) 1991-05-10 1992-11-26 The Salk Institute For Biological Studies CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-β SUPERFAMILY
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5661007A (en) 1991-06-25 1997-08-26 Genetics Institute, Inc. Bone morphogenetic protein-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP1475440A3 (en) 1993-01-12 2004-11-17 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
DE69433742T2 (de) 1993-05-12 2005-07-07 Genetics Institute, LLC, Cambridge Bmp-10 zusammensetzungen
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5831050A (en) 1993-06-07 1998-11-03 Creative Biomolecules, Inc. Morphogen cell surface receptor
EP0726948B1 (en) 1993-10-14 2007-02-28 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5658876A (en) * 1994-04-28 1997-08-19 The General Hospital Corporation Activin antagonists as novel contraceptives
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
CA2217545A1 (en) 1995-04-11 1996-10-17 Marc Vidal Reverse two-hybrid systems
US6132988A (en) * 1995-10-27 2000-10-17 Takeda Chemical Industries, Ltd. DNA encoding a neuronal cell-specific receptor protein
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6004780A (en) * 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US20050244867A1 (en) * 1996-03-26 2005-11-03 Human Genome Sciences, Inc. Growth factor HTTER36
EP0939816A1 (en) 1996-10-25 1999-09-08 G.D. SEARLE & CO. Circularly permuted erythropoietin receptor agonists
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
CA2297489A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6953662B2 (en) * 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
EP1015468A4 (en) 1997-08-29 2000-09-06 Human Genome Sciences Inc FOLLISTATINE-3
JP3992298B2 (ja) 1997-10-03 2007-10-17 中外製薬株式会社 天然ヒト型化抗体
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
EP1113799A4 (en) 1998-09-17 2004-06-09 Lilly Co Eli PROTEIN-BASED PREPARATION
CA2343715C (en) * 1998-09-22 2004-05-18 Long Yu New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6548634B1 (en) 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6777205B1 (en) * 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN1163262C (zh) * 1999-04-01 2004-08-25 上海益众生物技术有限公司 成骨生长肽药物组合物及制备方法和应用
AU777783B2 (en) 1999-04-19 2004-10-28 Kyowa Hakko Kogyo Co. Ltd. Proliferation inhibitor for androgen-independent tumor
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
HRP20020387A2 (en) 1999-11-12 2005-10-31 Maxygen Holdings Ltd. Interferon gamma conjugates
WO2001043763A1 (en) 1999-12-15 2001-06-21 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
US6627424B1 (en) 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
AU2001269709A1 (en) 2000-07-19 2002-02-05 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
US6632180B1 (en) 2000-09-07 2003-10-14 John H. Laragh Method for evaluating and treating hypertension
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
AU2002225670B2 (en) 2000-11-20 2006-05-11 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
EP1370287A2 (en) 2000-12-01 2003-12-17 Wyeth Method and composition for modulating bone growth
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
TW200526779A (en) * 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7294472B2 (en) 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
US20040121008A1 (en) 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
PT1390535E (pt) 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
AU2001286171B2 (en) * 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
JP2003012699A (ja) 2001-07-04 2003-01-15 Japan Science & Technology Corp 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
KR101021817B1 (ko) 2001-07-17 2011-03-17 데이진 가부시키가이샤 ＰＰＡＲ δ활성화 작용을 측정하는 것을 특징으로 하는 물질의 선택방법 및 약제
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20060234918A1 (en) 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US6998118B2 (en) 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
WO2003068801A2 (en) 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
MXPA04008150A (es) * 2002-02-21 2005-06-17 Wyeth Corp Gasp1: una proteina que contiene dominio de folistatina.
US20030219846A1 (en) 2002-02-28 2003-11-27 Pfizer Inc. Assay for activity of the ActRIIB kinase
US8053552B2 (en) 2002-04-18 2011-11-08 Mtm Laboratories, Ag Neopeptides and methods useful for detection and treatment of cancer
CA2497304A1 (en) 2002-08-16 2004-02-26 Wyeth Bmp-2 estrogen responsive element and methods of using the same
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2002953327A0 (en) 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
DE04708802T1 (de) 2003-02-07 2006-06-22 Prometic Biosciences Inc., Montreal Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
WO2004086953A2 (en) 2003-03-26 2004-10-14 The Board Of Trustees Of The University Of Arkansas Method for diagnosis and treatment of bone turnover
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
US7785587B2 (en) 2003-06-02 2010-08-31 Wyeth Therapeutic methods for muscular or neuromuscular disorders
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005009460A2 (en) 2003-07-25 2005-02-03 Medexis, S.A. Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
EP1706428B1 (en) 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2005094871A2 (en) * 2004-03-26 2005-10-13 Acceleron Pharma Inc. Bmp-3 propeptides and related methods
JP2008500816A (ja) 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
WO2005115439A2 (en) * 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof
EP1771557B1 (en) 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
ES2551852T3 (es) * 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
EP1794191B1 (en) 2004-08-05 2016-05-18 The Regents of The University of California Molecules with effects on cellular development and function
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
EP1804824B1 (en) 2004-09-29 2017-01-04 Icahn School of Medicine at Mount Sinai Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2006055689A2 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
US20060213667A1 (en) * 2005-03-28 2006-09-28 Mashburn Benny D Screen apparatus and method
JPWO2006115274A1 (ja) 2005-04-26 2008-12-18 味の素株式会社 骨髄赤血球前駆細胞分化促進剤
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
JP2007099764A (ja) 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
JP2009510093A (ja) 2005-09-28 2009-03-12 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆアンタゴニストならびにその使用方法
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
WO2007071023A1 (en) 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007075702A2 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
US7361510B2 (en) * 2006-01-20 2008-04-22 Beckman Coulter, Inc. Methods of detection of iron deficiency
CA2637375A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2642662A1 (en) 2006-02-28 2007-09-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2007120767A2 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
BRPI0713096A2 (pt) * 2006-05-09 2012-10-16 Hemaquest Pharmaceuticals Inc métodos para tratar distúrbios sangüìneos
BRPI0714882A2 (pt) * 2006-07-21 2013-05-21 Lyne Lab composiÇço lÍquida de acetato de cÁlcio e uso de uma soluÇço aquosa que compreende entre cerca de 7% (p/v) e cerca de 21% (p/v) de acetato de cÁlcio
GB0615129D0 (en) 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008060139A1 (en) 2006-11-17 2008-05-22 Erasmus University Medical Center Rotterdam Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
WO2008073292A2 (en) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
AU2007332473B2 (en) 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
EP2468291B1 (en) 2006-12-18 2017-11-22 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
CA2677007A1 (en) * 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US20090017019A1 (en) * 2007-06-01 2009-01-15 Wyeth Methods and compositions for modulating bmp-10 activity
WO2009009059A1 (en) 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
LT2170396T (lt) 2007-08-03 2017-03-10 Summit (Oxford) Limited Vaistų deriniai, skirti diušeno raumenų distrofijos gydymui
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715938D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
WO2009025651A1 (en) 2007-08-17 2009-02-26 University Of Maine System Board Of Trustees Biologically active peptide and method of using the same
WO2009035629A1 (en) 2007-09-13 2009-03-19 Ludwig Institute Of Cancer Research Method for modifying cellular immune response by modulating activin activity
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8043620B2 (en) 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
FR2930460B1 (fr) * 2008-04-25 2010-05-28 Valois Sas Distributeur de fragrance.
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
JP2011523357A (ja) 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
US20100008918A1 (en) 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
NZ590326A (en) 2008-06-26 2013-05-31 Acceleron Pharma Inc Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5922928B2 (ja) * 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
ME02652B (me) 2008-11-26 2017-06-20 Amgen Inc Stabilizovana varijanta aktivin iib receptora
EP2387412A4 (en) * 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
NO2424895T3 (pl) 2009-04-27 2018-02-03
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2796121T3 (es) 2009-08-13 2020-11-25 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
CA2773494A1 (en) 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
CA2779472C (en) 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
PL2726099T3 (pl) 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
CA2852683A1 (en) 2011-10-17 2013-04-25 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
BR112014009949A8 (pt) 2011-10-28 2018-01-16 Paranta Biosciences Ltd métodos de tratamento de hipersecreção de muco e uso de agentes
JP6145112B2 (ja) 2011-12-19 2017-06-07 アムジエン・インコーポレーテツド 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP3521310A1 (en) 2012-06-14 2019-08-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenic protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
CN104411720B (zh) 2012-07-02 2018-05-11 协和发酵麒麟株式会社 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
CN104968801B (zh) 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血症的生物标志物
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
CA3240136A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
WO2014093531A1 (en) 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
US20140220033A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an Anti-Activin-A Compound to a Subject
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
TW201536318A (zh) 2013-08-14 2015-10-01 Novartis Ag 治療偶發性包涵體肌炎之方法
JP2017505428A (ja) 2013-12-16 2017-02-16 パランタ バイオサイエンス リミテッド 診断及び治療の方法
WO2015108972A1 (en) 2014-01-14 2015-07-23 Santa Maria Biotherapeutics, Inc. Activin inhibitor response prediction and uses for treatment
US20170248609A1 (en) 2014-01-27 2017-08-31 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
JP6601687B2 (ja) 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
JP6649895B2 (ja) 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
AU2015274293A1 (en) 2014-06-13 2017-02-02 Amgen Inc. Formulated receptor polypeptides and related methods

Also Published As

Publication number Publication date
IL200242B (en) 2018-03-29
ES2394123T3 (es) 2013-01-22
WO2008100384A3 (en) 2008-12-11
EA018221B1 (ru) 2013-06-28
BRPI0807506A2 (pt) 2013-07-30
TWI667038B (zh) 2019-08-01
CA2913992A1 (en) 2008-08-21
JP6132861B2 (ja) 2017-05-24
KR20160129095A (ko) 2016-11-08
SI2120999T1 (sl) 2012-12-31
KR101670417B1 (ko) 2016-11-10
IL257848B (en) 2021-04-29
EP2481415B1 (en) 2019-09-11
JP2020176139A (ja) 2020-10-29
TWI525102B (zh) 2016-03-11
TW201907953A (zh) 2019-03-01
KR20210082540A (ko) 2021-07-05
US20090142333A1 (en) 2009-06-04
CN101687016B (zh) 2014-12-31
JP2018162312A (ja) 2018-10-18
TWI459963B (zh) 2014-11-11
AU2008216896B2 (en) 2013-06-20
KR20200054317A (ko) 2020-05-19
MX2009008510A (es) 2010-01-15
CA2677605A1 (en) 2008-08-21
EP2120999A2 (en) 2009-11-25
IL257848A (en) 2018-04-30
TW201808334A (zh) 2018-03-16
CA3039330C (en) 2021-11-09
EA201690994A1 (ru) 2016-09-30
AU2008216896A1 (en) 2008-08-21
IL281715A (en) 2021-05-31
CA2677605C (en) 2016-01-19
AU2008216896A2 (en) 2011-07-14
TW201934141A (zh) 2019-09-01
US9572865B2 (en) 2017-02-21
JP5574711B2 (ja) 2014-08-20
KR20190026047A (ko) 2019-03-12
EA201300116A1 (ru) 2013-09-30
KR20180083967A (ko) 2018-07-23
TW202140531A (zh) 2021-11-01
US20170190784A1 (en) 2017-07-06
EA025371B1 (ru) 2016-12-30
CA3039330A1 (en) 2008-08-21
CY1113963T1 (el) 2016-07-27
HRP20120947T1 (hr) 2012-12-31
JP2013224317A (ja) 2013-10-31
JP2010518079A (ja) 2010-05-27
JP2015091870A (ja) 2015-05-14
CA2913992C (en) 2019-05-21
BRPI0807506B1 (pt) 2022-02-15
IL200242A0 (en) 2010-04-29
AR065289A1 (es) 2009-05-27
US8173601B2 (en) 2012-05-08
TW201615660A (zh) 2016-05-01
TWI606062B (zh) 2017-11-21
US20210261682A1 (en) 2021-08-26
KR20100014850A (ko) 2010-02-11
JP2017071624A (ja) 2017-04-13
CN101687016A (zh) 2010-03-31
CN104548056B (zh) 2022-09-09
HK1137366A1 (en) 2010-07-30
US20130004489A1 (en) 2013-01-03
ME02333B (me) 2013-04-30
TW200900076A (en) 2009-01-01
TW201500371A (zh) 2015-01-01
TR200906329T1 (tr) 2010-01-21
EP2484372A1 (en) 2012-08-08
CN104189889A (zh) 2014-12-10
WO2008100384A2 (en) 2008-08-21
DK2120999T3 (da) 2012-12-03
KR20150115965A (ko) 2015-10-14
PT2120999E (pt) 2012-12-10
CN104548056A (zh) 2015-04-29
EP2481415A1 (en) 2012-08-01
ES2756725T3 (es) 2020-04-27
KR101672156B1 (ko) 2016-11-02
MX368173B (es) 2019-09-23
RS52535B (sr) 2013-04-30
EA200970747A1 (ru) 2010-02-26
EP2120999B1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
SI2120999T1 (sl) FARMACEVTSKI SESTAVKI, KI VSEBUJEJO AKTIVIN-ActRIIA ANTAGONISTE IN NJIHOVA UPORABA PRI PREPREÄŚEVANJU ALI ZDRAVLJENJU MULTIPLEGA MIELOMA
IL204442A (en) Inhibitors of atpase-0fif, medicinal preparations containing them and their use
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
IL213365A (en) Imidazopyrazine and their pharmaceutical preparations
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL200905A0 (en) Compounds and compositions comprising the same for use in treating hepatitis c
PT2142220E (pt) Agentes hemostáticos à base de argila e dispositivos para a sua administração
IL199859A (en) Skills for transferring ethylene blocking agents and / or factors that help create ethylene
PL2653873T1 (pl) Kompozycje i zastosowania do leczenia stwardnienia rozsianego
ZA201001616B (en) Cleaning and/or treatment compositions
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
ZA200806842B (en) Imidazole-based compounds,compositions comprising them and methods of their use
IL223784A (en) Antimicrobial peptide, preparations and methods of use
SI2154966T1 (sl) Benzimidazoli in njihovi farmacevtski sestavki
GB2447522B (en) Synergistic preservetive systems and their use in topical compositions
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
EP2119708A4 (en) TETRAHYDROQUINAZOLINE COMPOUNDS AND THEIR USE IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT AND PREVENTION OF VIROSES
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
IL196411A0 (en) Anti-cocaine compositions and treatment
EP2029132A4 (en) ANTIHISTAMINE COMPOSITIONS AND THEIR USE
GB0614365D0 (en) Pharmaceutical compositions and their use
GB0714500D0 (en) composition and treatment
GB0720518D0 (en) Compositions and their use